

P R E S S R E L E A S E

Lelystad, the Netherlands, 29 June 2010

FORNIX SHAREHOLDERS APPROVE SALE OF ALLERGY DIVISION

At the Extraordinary Annual General Meeting of Shareholders of biopharmaceutical company Fornix BioSciences N.V. (Euronext Amsterdam: AFORBI) held in Lelystad, the Netherlands, the shareholders have approved the previously announced sale (effective 1 July 2010) of Fornix's Allergy Division (Artu Biologicals Europe and Artu Biologicals Onroerend Goed) to the Danish-based pharmaceutical company ALK-Abelló and the agreements in relation to the sale (the Transaction).

For more information about the Transaction we refer to the press release of Fornix published on 1 June 2010 as well as the shareholder circular published on the same date. Fornix and ALK expect to complete the Transaction in early July 2010; that is to say, the transfer of ownership of all outstanding shares in the capital of Artu and Artu OG to ALK upon payment of the estimated purchase price.

E N D O F P R E S S R E L E A S E

For more information, please contact: Fornix BioSciences N.V.

C.L. Bergman, CEO
Tel. +31 (320) 26 77 99
Website: www.fornix.nl

Profile of Fornix BioSciences N.V.

Fornix BioSciences N.V. is a listed company (Euronext Amsterdam: AFORBI) which engages mainly in the development and sale of diagnostic and therapeutic allergen products and the distribution of medical aids and medical and nursing consumables.

Fornix BioSciences N.V. has sites in Lelystad, Beuningen and Hamburg. The company currently has 138 employees and operates mainly in the Netherlands and Germany. Its activities are conducted by two divisions, the Allergy Division consisting of Artu Biologicals Europe and the Medical Aids Division. The activities of Artu Biologicals Deutschland are conducted separately from these two divisions.

The Allergy Division focuses on the development, production and sale of a wide range of patient-friendly immunotherapeutic products including the Oralgen[®] and Igevac[®] brands. These products are administered in the causal treatment of allergies triggered by various allergens, such as grass and tree pollen and house-dust mites. The development programme is supported by high-quality R&D activities and pan-European clinical studies on the effectiveness and safety of the various



products. Clinical research should over time lead to the registration of the company's most important allergen products Oralgen[®] Grass Pollen, Tree Pollen and House-dust mite. In the coming years, the company intends to increase its focus on allergen products and to expand its position in the growing immunotherapy market in Europe.

Artu Biologicals Deutschland in Hamburg carries a growing range of medical aids in Germany on an exclusive basis. The Oralgen[®] equivalent Igevac[®] is also distributed in this market on a named-patient basis.

The Medical Aids Division consists of Laprolan, located in Beuningen. The division focuses on the sale, marketing and distribution of a wide range of medical aids and medical and nursing consumables.